What Fucidin Leo Treats: Main Uses and Benefits

Fucidin Leo (fusidic acid) is commonly used for the topical treatment of primary and secondary bacterial skin infections caused by susceptible bacteria. The medication plays a role in managing infections in conditions characterized by periods of heightened symptoms.

The therapeutic benefit is relevant in contexts where additional symptomatic support is needed, including conditions such as Impetigo (weeping, crusty sores), Erythrasma, and infected areas of eczema, dermatitis, or wounds. Fucidin is indicated to treat conditions where the skin is infected by bacteria, including specific examples like Impetigo, Erythrasma, and infected cuts and burns.

The medication supports symptom management by being relevant for easing symptoms related to inflammatory or irritative states that accompany an active skin infection. This may include helping to reduce the swelling, redness, and physical discomfort at the site of infection. By helping to manage infection-driven symptoms, Fucidin Leo contributes to improved comfort during periods of heightened symptoms. It is often used when symptoms intensify and supportive relief is needed, and may assist with maintaining functional stability.

“The treatment is commonly used to help manage the symptoms associated with the surface infection.”

Quick Fact: Relevant for Managing Infection-Related Swelling and Discomfort

Regulatory References

1. Details for: FUCIDIN - Drug and Health Product Register

The eligibility for using topical Fucidin Leo is determined by strict regulatory guidelines regarding population groups and known patient history.

Populations for Whom Use is Contraindicated

The medicine is contraindicated in any patient with a documented history of hypersensitivity to the active substance, fusidic acid or sodium fusidate, or to any of the non-medicinal ingredients in the specific formulation.

Age-Group and General Eligibility

Category	Regulatory Status
Adults and Children	Approved for use across the entire paediatric and adult population.
Older Adults	No dosage alterations are noted as necessary in the elderly.
Organ Function	No restrictions are required for renal or hepatic impairment for the topical form, as systemic absorption is negligible.

Pregnancy and Lactation Eligibility

Topical Fucidin Leo can be used during pregnancy, as effects on the unborn child are not anticipated due to the negligible amount of drug absorbed into the body. Use is also permitted during breastfeeding, with the regulatory guidance that application on the breast area should be avoided to prevent accidental infant ingestion.

Fucidin Leo Interactions with other medicines and products

Interactions with systemically administered medicinal products are considered minimal for the topical formulation of Fucidin Leo (cream or ointment) due to its negligible systemic absorption, as noted in official regulatory documents. However, the active ingredient, Fusidic Acid, has a defined interaction profile when used systemically.

Classification	Interacting Agents	Practical Regulatory Rule
Formal Contraindication	HMG-CoA reductase inhibitors (Statins, e.g., Atorvastatin, Simvastatin)	Co-administration of the systemic antibiotic and statins is prohibited due to the serious risk of rhabdomyolysis [GOV.UK Drug Safety Update].
Timing Restriction	Statins	Statin treatment must be discontinued throughout the systemic Fusidic Acid course and may be re-introduced seven days after the final antibiotic dose [HPRA SmPC].
Exposure Modification	HIV Protease Inhibitors (e.g., Ritonavir, Saquinavir); Oral Anticoagulants (Coumarin derivatives)	Co-administration may cause increased plasma concentrations of both Fusidic Acid and the protease inhibitor, potentially leading to hepatotoxicity. The anticoagulant effect of coumarin derivatives may also be altered [FDA Verification Portal].
Population Caution	Hepatic Dysfunction; Neonates	Systemic use requires caution and monitoring in patients with impaired hepatic function. Particular care is advised in neonates due to the theoretical risk of kernicterus [HPRA SmPC].

Targeted Inhibition of Microbial Protein Synthesis

Fusidic Acid acts as a highly specific inhibitor by physically locking the enzyme Elongation Factor G (EF-G) onto the bacterial ribosome. This molecular blockade prevents the ribosome from completing its cycle, immediately arresting the cell’s ability to manufacture essential structural and functional proteins.

---

Mechanistic Consequences and Boundaries

The interruption of protein synthesis places the susceptible microbial population into a state of bacteriostasis, characterized by halted growth and replication. This physiological outcome reduces the microbial burden and results in arrested pathogen replication, allowing interaction with host defense mechanisms. The mechanistic effect is constrained by resistance mechanisms, such as gene modifications that alter the EF-G target or enable the bacteria to actively release the drug-stalled ribosomal complex.

Official Administration Guidelines for Fucidin Leo

Fucidin Leo (fusidic acid/sodium fusidate) is administered according to the specific formulation, which dictates the route and schedule of use.

---

Dosage Forms and Routes

Feature	Administration Principle (Label-Based)
Cutaneous Use	Administered as a cream or ointment containing 20 mg/g (2%), applied directly to the affected skin area.
Systemic Use	Administered orally as 250 mg tablets or suspension, or via intravenous injection for severe infections.

---

Standard Dosing and Frequency

For topical application, a small amount is generally applied to the lesion three or four times daily; this frequency may be reduced to once or twice daily if the treated area is covered by a dressing. For systemic oral use, the standard adult dose is 250 mg of sodium fusidate, typically taken twice daily. In cases of severe systemic infection, the oral regimen may be increased to 500 mg three times daily. Intravenous administration is generally 500 mg three times daily, requiring slow infusion over at least two hours.

---

Contextual Instructions and Duration

Oral tablets should be swallowed whole and are generally taken without food. The oral suspension must be shaken well before measurement. The standard duration for a course of topical therapy is typically 7 to 14 days. Pediatric systemic dosing is based on body weight, and no dose adjustment is generally required for patients with renal impairment or older adults. When applying topical forms to the face, care must be taken to avoid contact with the eyes.

Research evidence / Overview of studies for Fucidin Leo

Evidence for use in Primary Bacterial Skin Infections (e.g., Impetigo)

Research exploring topical Fucidin Leo (fusidic acid) for localized primary bacterial skin infections has primarily involved short-term Randomized Controlled Trials (RCTs) and systematic reviews, often comparing the agent to placebo or other topical antibiotics. Studies monitored clinical success and bacteriological eradication over defined time intervals. Trials reported measurements related to clinical success outcomes that were observed more frequently in the topical fusidic acid group when compared to a placebo. Research describes changes measured during the study period, with primary assessments typically conducted between seven and fourteen days.

Evidence for use in Secondarily Infected Dermatoses (e.g., Infected Eczema)

Studies for infected dermatoses also involve RCTs and systematic reviews of the single agent or combination product (with a topical corticosteroid). Findings were mixed across studies. Some systematic reviews reported that when the combination was compared against the corticosteroid alone, clinical outcomes did not show a statistically significant difference in certain measured severity scores. Uncertainty exists regarding the role of the antibiotic component in studies of milder cases. A further area of uncertainty is the documented association of topical use with the increased presence of fusidic acid-resistant S. aureus isolates in some observed patients.

Long-term Outcomes, Specific Populations, and Evidence Gaps

Long-term effects are not fully established regarding the durability of the observed patterns or the stability of the condition beyond the short study interval, as follow-up durations were limited. Data for certain groups, such as pregnant or breastfeeding individuals, remain insufficient. The surveillance of antibiotic resistance is a primary area of ongoing research. Additionally, certainty remains low regarding findings from comparative trials examining differences in outcomes between fusidic acid and other comparable therapies, and evidence quality varies across studies.

Common questions about Fucidin Leo (FAQ)

---

Q: What is the difference between Fucidin Leo Cream and Ointment?

Regulatory documents and medical literature indicate that Fucidin Leo Cream is generally suitable for use on large lesions or areas that do not require a dressing. The Ointment has a greasier texture; official labeling indicates its use for specific lesions or areas that may be covered by a dressing. Both topical preparations contain the same active ingredient and are considered equally effective for treating skin infections.

---

Q: What should I do if I miss an application of the cream?

If an application is forgotten, official patient information describes that it can be applied as soon as the patient remembers. If it is almost time for the next scheduled application, the recommendation is to skip the missed dose and continue with the regular routine. Official guidance states that a double application should not be used to compensate for a forgotten dose.

---

Q: How quickly does Fucidin Leo start to work for a skin infection?

According to official patient information, the treated skin condition should begin to show improvement within a few days of starting treatment. Even if the condition shows quick improvement, the prescribed course of treatment duration should be completed, as directed by the prescribing health professional.

---

Q: Is Fucidin Leo available over the counter?

Official prescribing information indicates that Fucidin Leo (fusidic acid) is typically a prescription-only medicine. This indicates that obtaining the medication generally requires a valid prescription from a qualified healthcare provider.

---

Q: Can I drink alcohol while taking Fucidin Leo?

Official product information for the topical cream or ointment states that the active ingredient has minimal systemic absorption, meaning very little enters the bloodstream. Regulatory documents indicate that due to this minimal absorption, the risk of clinically relevant interactions with systemically administered medicinal products is minimal for the topical formulation. Formal interaction studies with alcohol have not been reported.

---

Q: What is the proper storage temperature for Fucidin Leo?

Official labeling requires that the medicine not be stored at temperatures exceeding 30 C for both the cream and the ointment. Check the product packaging for any specific storage conditions or recommended temperature ranges for the medicine before and after opening.

---

Q: Are there any foods I should avoid while using Fucidin Leo?

Regulatory patient information indicates that, for the topical cream or ointment, there are no specific foods, herbal remedies, or supplements known to cause problems when used in conjunction with this medicine.

---

Storage and Disposal Requirements

Fucidin Leo (fusidic acid) must be stored strictly according to official regulatory labeling to ensure product stability. The medicine must be kept out of the sight and reach of children at all times.

Storage Conditions

Condition	Requirement
Temperature	Do not store at temperatures exceeding 30 C for both Cream and Ointment.
Post-Opening Shelf-Life (Cream)	Must be discarded 28 days after first opening.
Post-Opening Shelf-Life (Ointment)	Must be discarded 3 months after first opening.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medicine should not be thrown away with household waste or disposed of via wastewater. Consult a pharmacist for guidance on proper pharmaceutical waste handling.